Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients

By Mahabaleshwarkar Rohan K.   Yang Yi   Datar Manasi V.   Bentley John P.   Strum Matthew W.   Banahan Benjamin F.   Null Kyle D.  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 315-323

Informa Healthcare

Access to resources Recommend Favorite

Adiponectin in renal disease - a review of the evidence as a risk factor for cardiovascular and all-cause mortality

By Connelly Philip W.   Prasad G. V.  

Critical Reviews in Clinical Laboratory Sciences, Vol. 49, Iss. 5-6, 2012-12 ,pp. : 218-231

Informa Healthcare

Access to resources Recommend Favorite

The effect of sarcopenic obesity on cardiovascular disease and all-cause mortality in older people

By  

Reviews in Clinical Gerontology, Vol. 25, Iss. 2, 2015-05 ,pp. : 86-97

Cambridge University Press

Access to resources Recommend Favorite

Cardiovascular and all‐cause mortality in patients with intermittent claudication and critical limb ischaemia

By  

BRITISH JOURNAL OF SURGERY, Vol. 105, Iss. 3, 2018-02 ,pp. : 252-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 344-351

John Wiley & Sons Inc

Access to resources Recommend Favorite